Email This Release
Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Terms of Use
|
© 2024 Business Wire